Published in Am J Psychiatry on January 01, 2004
Psychiatric comorbidities and schizophrenia. Schizophr Bull (2008) 2.69
How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull (2009) 1.69
A common genetic variant in the neurexin superfamily member CNTNAP2 is associated with increased risk for selective mutism and social anxiety-related traits. Biol Psychiatry (2010) 1.62
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry (2014) 1.39
Avoidant personality disorder is a separable schizophrenia-spectrum personality disorder even when controlling for the presence of paranoid and schizotypal personality disorders The UCLA family study. Schizophr Res (2007) 1.06
Association of stigma, self-esteem, and symptoms with concurrent and prospective assessment of social anxiety in schizophrenia. Clin Schizophr Relat Psychoses (2010) 0.98
Social appraisal in chronic psychosis: role of medial frontal and occipital networks. J Psychiatr Res (2010) 0.92
Predictors of remission, schizophrenia, and bipolar disorder in adolescents with brief psychotic disorder or psychotic disorder not otherwise specified considered at very high risk for schizophrenia. J Child Adolesc Psychopharmacol (2008) 0.89
Emotional experience predicts social adjustment independent of neurocognition and social cognition in schizophrenia. Schizophr Res (2010) 0.85
A composite scale applied to evaluate anxiety in schizophrenic patients (SAES). Eur Arch Psychiatry Clin Neurosci (2013) 0.82
Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative. Am J Psychiatry (2004) 0.79
Schizophrenia and Suicide Attempts: Findings from a Representative Community-Based Canadian Sample. Schizophr Res Treatment (2016) 0.78
Anhedonia in the psychosis risk syndrome: associations with social impairment and basal orbitofrontal cortical activity. NPJ Schizophr (2015) 0.77
Co-morbid anxiety disorders in patients with schizophrenia in a tertiary institution in South East Nigeria: prevalence and correlates. Afr Health Sci (2015) 0.77
Experiencing malevolent voices is associated with attentional dysfunction in psychotic patients. Scand J Psychol (2013) 0.77
Sex-dependent behavioral effects and morphological changes in the hippocampus after prenatal invasive interventions in rats: implications for animal models of schizophrenia. Clinics (Sao Paulo) (2010) 0.76
Frequent Comorbidity and Predictors of Social Anxiety in Persons With Schizophrenia: A Retrospective Cohort Study. Prim Care Companion CNS Disord (2015) 0.76
Virtual environments using video capture for social phobia with psychosis. Cyberpsychol Behav Soc Netw (2013) 0.76
Prevalence of comorbid anxiety disorders in schizophrenia. Ind Psychiatry J (2017) 0.75
Protocol for a systematic review and meta-analysis of cognitive-behavioural therapy for social anxiety disorder in psychosis. Syst Rev (2014) 0.75
The moderating effects of perceived intentionality: exploring the relationships between ideas of reference, paranoia and social anxiety in schizotypy. Cogn Neuropsychiatry (2014) 0.75
A case report of cognitive behavioural therapy for social anxiety in an ultra-high risk patient. Early Interv Psychiatry (2013) 0.75
Severity of psychotic episodes in predicting concurrent depressive and anxiety features in acute phase schizophrenia. BMC Psychiatry (2014) 0.75
Comorbidity and disability in outpatients with schizophrenia. Am J Psychiatry (2005) 0.75
Paranoid Thoughts in Adolescents with Social Anxiety Disorder. Child Psychiatry Hum Dev (2016) 0.75
Psychotic experiences and social functioning: a longitudinal study. Soc Psychiatry Psychiatr Epidemiol (2013) 0.75
Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet (2007) 14.05
Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry (2009) 3.32
A replication of the Autism Diagnostic Observation Schedule (ADOS) revised algorithms. J Am Acad Child Adolesc Psychiatry (2008) 2.82
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry (2008) 2.64
Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review. Neuropsychopharmacology (2009) 2.60
Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry (2007) 2.53
Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry (2006) 2.50
The neuroscience of affiliation: forging links between basic and clinical research on neuropeptides and social behavior. Horm Behav (2006) 2.10
The Shorter PROMIS Questionnaire and the Internet Addiction Scale in the assessment of multiple addictions in a high-school population: prevalence and related disability. CNS Spectr (2006) 1.74
Oxytocin selectively improves empathic accuracy. Psychol Sci (2010) 1.69
Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry (2004) 1.66
Mutation screening of the PTEN gene in patients with autism spectrum disorders and macrocephaly. Am J Med Genet B Neuropsychiatr Genet (2007) 1.65
Reliability and validity of the pathological gambling adaptation of the Yale-Brown Obsessive-Compulsive Scale (PG-YBOCS). J Gambl Stud (2005) 1.64
Oxytocin can hinder trust and cooperation in borderline personality disorder. Soc Cogn Affect Neurosci (2010) 1.64
Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract (2012) 1.49
Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial. JAMA Pediatr (2013) 1.47
Obsessive-compulsive disorder: a review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-V. Depress Anxiety (2010) 1.47
The Gambling Symptom Assessment Scale (G-SAS): a reliability and validity study. Psychiatry Res (2009) 1.46
Selective serotonin reuptake inhibitors in autism: a review of efficacy and tolerability. J Clin Psychiatry (2006) 1.44
Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol (2002) 1.39
Fronto-thalamo-striatal gray and white matter volumes and anisotropy of their connections in bipolar spectrum illnesses. Biol Psychiatry (2005) 1.35
Volumetric analysis and three-dimensional glucose metabolic mapping of the striatum and thalamus in patients with autism spectrum disorders. Am J Psychiatry (2006) 1.31
Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol Autism (2012) 1.30
Oxytocin and experimental therapeutics in autism spectrum disorders. Prog Brain Res (2008) 1.29
Epidemiologic and clinical updates on impulse control disorders: a critical review. Eur Arch Psychiatry Clin Neurosci (2006) 1.25
Symptom domains in autism and related conditions: evidence for familiality. Am J Med Genet (2002) 1.21
Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. Psychopharmacology (Berl) (2008) 1.16
Should an obsessive-compulsive spectrum grouping of disorders be included in DSM-V? Depress Anxiety (2010) 1.15
Multiplex ligation-dependent probe amplification for genetic screening in autism spectrum disorders: efficient identification of known microduplications and identification of a novel microduplication in ASMT. BMC Med Genomics (2008) 1.15
Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression. J Clin Psychiatry (2008) 1.12
Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. Prog Neuropsychopharmacol Biol Psychiatry (2006) 1.12
Treating body dysmorphic disorder with medication: evidence, misconceptions, and a suggested approach. Body Image (2008) 1.11
Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry (2015) 1.09
Autism-related routines and rituals associated with a mitochondrial aspartate/glutamate carrier SLC25A12 polymorphism. Am J Med Genet B Neuropsychiatr Genet (2008) 1.08
WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr (2003) 1.06
Autism and oxytocin: new developments in translational approaches to therapeutics. Neurotherapeutics (2010) 1.05
In vivo 1H-magnetic resonance spectroscopy study of the attentional networks in autism. Brain Res (2010) 1.03
Psychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability. J Child Adolesc Psychopharmacol (2008) 1.03
Impulsive-compulsive sexual behavior. CNS Spectr (2006) 1.03
Exploring the manifestations of anxiety in children with autism spectrum disorders. J Autism Dev Disord (2013) 1.02
Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry (2010) 1.02
An open-label trial of venlafaxine in body dysmorphic disorder. CNS Spectr (2008) 1.02
Regional glucose metabolism within cortical Brodmann areas in healthy individuals and autistic patients. Neuropsychobiology (2004) 1.00
Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review. J Clin Psychiatry (2006) 0.99
A double-blind study of citalopram versus placebo in the treatment of compulsive sexual behaviors in gay and bisexual men. J Clin Psychiatry (2006) 0.99
Serotonin dysfunction in pathological gamblers: increased prolactin response to oral m-CPP versus placebo. CNS Spectr (2006) 0.99
Impaired structural connectivity of socio-emotional circuits in autism spectrum disorders: a diffusion tensor imaging study. PLoS One (2011) 0.98
Is compulsive buying a real disorder, and is it really compulsive? Am J Psychiatry (2006) 0.98
A review of pharmacologic treatments for obsessive-compulsive disorder. Psychiatr Serv (2003) 0.97
Psychopharmacologic interventions for repetitive behaviors in autism spectrum disorders. Child Adolesc Psychiatr Clin N Am (2008) 0.97
Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. CNS Drugs (2009) 0.96
Lack of evidence for association of the serotonin transporter gene SLC6A4 with autism. Biol Psychiatry (2006) 0.95
Lithium and valproate treatment of pathological gambling: a randomized single-blind study. J Clin Psychiatry (2002) 0.95
Familial associations of intense preoccupations, an empirical factor of the restricted, repetitive behaviors and interests domain of autism. J Child Psychol Psychiatry (2009) 0.94
Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study. Br J Psychiatry (2010) 0.93
Escitalopram in the treatment of impulsive-compulsive internet usage disorder: an open-label trial followed by a double-blind discontinuation phase. J Clin Psychiatry (2008) 0.93
A preliminary study of cortisol and norepinephrine reactivity to psychosocial stress in borderline personality disorder with high and low dissociation. Psychiatry Res (2006) 0.93
Evidence that eicosapentaenoic acid is effective in treating autism. J Clin Psychiatry (2003) 0.93
Peritraumatic reactions associated with the World Trade Center disaster. Am J Psychiatry (2003) 0.93
Functional deficits of the attentional networks in autism. Brain Behav (2012) 0.92
Relationship of personality to dissociation and childhood trauma in borderline personality disorder. CNS Spectr (2003) 0.92
Obsessive-compulsive disorder: diagnostic and treatment issues. Psychiatr Clin North Am (2009) 0.91
Relationship between whole blood serotonin and repetitive behaviors in autism. Psychiatry Res (2009) 0.91
Is obsessive-compulsive disorder an anxiety disorder? Prog Neuropsychopharmacol Biol Psychiatry (2006) 0.89
Brief report: parental age and the sex ratio in autism. J Autism Dev Disord (2009) 0.88
Dissociation and posttraumatic stress 1 year after the World Trade Center disaster: follow-up of a longitudinal survey. J Clin Psychiatry (2005) 0.88
Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. Int Clin Psychopharmacol (2006) 0.87
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry (2002) 0.87
WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. CNS Spectr (2003) 0.87
A double-blind, placebo-controlled trial of topiramate for pathological gambling. World J Biol Psychiatry (2011) 0.87
Association analysis of the NrCAM gene in autism and in subsets of families with severe obsessive-compulsive or self-stimulatory behaviors. Psychiatr Genet (2006) 0.86
Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry (2002) 0.85
The 5-HT(2A) receptor and serotonin transporter in Asperger's disorder: A PET study with [¹¹C]MDL 100907 and [¹¹C]DASB. Psychiatry Res (2011) 0.85
Brain stimulation techniques in the treatment of obsessive-compulsive disorder: current and future directions. CNS Spectr (2005) 0.85
Family-based association study of TPH1 and TPH2 polymorphisms in autism. Am J Med Genet B Neuropsychiatr Genet (2006) 0.84
A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. J Clin Psychiatry (2004) 0.84
Characterizing impulsivity profile in patients with obsessive-compulsive disorder. Int J Psychiatry Clin Pract (2013) 0.83
rTMS age-dependent response in treatment-resistant depressed subjects: a mini-review. CNS Spectr (2012) 0.83
Increased repetitive behaviours and prolactin responsivity to oral m-chlorophenylpiperazine in adults with autism spectrum disorders. Int J Neuropsychopharmacol (2004) 0.82
Nefazodone treatment of pathological gambling: a prospective open-label controlled trial. J Clin Psychiatry (2002) 0.82
Diagnosis and treatment of body dysmorphic disorder in adolescents. Curr Psychiatry Rep (2002) 0.82
Bipolar disorder and comorbid attention deficit hyperactivity disorder. A distinct clinical phenotype? Clinical characteristics and temperamental traits. World J Biol Psychiatry (2010) 0.82
Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients. Neuropsychobiology (2006) 0.81
Comorbidity in compulsive hoarding: a case report. CNS Spectr (2004) 0.81
Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorder. Compr Psychiatry (2009) 0.81
Serotonin-1D hypothesis of obsessive-compulsive disorder: an update. J Clin Psychiatry (2004) 0.81
Effects of age and symptomatology on cortical thickness in autism spectrum disorders. Res Autism Spectr Disord (2013) 0.81
WCA recommendations for the long-term treatment of panic disorder. CNS Spectr (2003) 0.80
Factor analysis of repetitive behaviors in Autism as measured by the Y-BOCS. J Neuropsychiatry Clin Neurosci (2011) 0.80
Antiepileptic medications in autism spectrum disorder: a systematic review and meta-analysis. J Autism Dev Disord (2014) 0.80
Mutation analysis of the NSD1 gene in patients with autism spectrum disorders and macrocephaly. BMC Med Genet (2007) 0.79
Design and subject characteristics in the federally-funded citalopram trial in children with pervasive developmental disorders. J Autism Dev Disord (2012) 0.79
OCSDs in the forthcoming DSM-V. CNS Spectr (2007) 0.79
Comorbidity issues in the pharmacological treatment of Pathological Gambling: a critical review. Clin Pract Epidemiol Ment Health (2005) 0.79
Cognitive event-related potentials differentiate schizophrenia with obsessive-compulsive disorder (schizo-OCD) from OCD and schizophrenia without OC symptoms. Psychiatry Res (2009) 0.78
An open-label trial of divalproex extended-release in the treatment of borderline personality disorder. CNS Spectr (2007) 0.78
Development and validation of the appearance and performance enhancing drug use schedule. Addict Behav (2011) 0.78